This week 14 November was World Diabetes Day. The number of people living with diabetes worldwide is rapidly rising, with an estimated 422 million adults affected in 2014 compared with 108 million in 1980. As the issue becomes more pressing, research is increasingly focusing on the condition and the factors that may influence the risk of it developing. A recent study, in particular, has found a strong link between a higher intake of vitamin D in childhood and a decreased risk of type 1 diabetes.
In the next installment of our brain health blog series, we will be reviewing the new research presented at the International Carotenoids Society‘s (ICS) symposium. The 18th ICS Symposium was a five day long event in Switzerland, hosting over 80 talks to almost 300 attendees. One topic of particular interest was the role of macular carotenoids, particularly lutein, in the brain. The benefits of lutein for the eyes are well documented, but emerging science is highlighting uses for cognitive health too. A variety of new studies on the subject were presented at the symposium by various speakers.
Alzheimer’s disease is the most common cause of dementia, and is expected to affect 131.5 million people by 2050. With this in mind, it’s clear to see why so much research is being carried out to help prevent, treat and cure Alzheimer’s disease.
Vitamin C has long been associated with immunity and, when faced with the common cold, a glass of orange juice is often the first thing people turn to for a boost. However, mounting evidence suggests that the health benefits of vitamin C may reach further than previously thought, particularly in supporting cardiovascular health. Notably, a study recently published in Nutrients has highlighted that an increased intake of the vitamin may significantly reduce the risk of cardiovascular mortality (CVM) and, in some models, the risk of cardiovascular disease (CVD), including myocardial infarction and stroke. Following World Heart Day 2017, read on to discover the role of vitamin C in cardiovascular health.
Lutein and zeaxanthin supplementation may slow progression of age-related macular degeneration and save EU billions in healthcare costs
Eye health is a leading health concern worldwide and, with 17.1 million people across the European Union (EU) alone suffering from age-related macular degeneration (AMD), it is clear to see why.1 AMD is a progressive degenerative eye disease and one of the main causes of vision loss.2 It affects the central vision, leaving those affected unable to see well directly ahead of them and potentially leading to a loss of independence and an inability to perform daily tasks. However, a new study by Frost & Sullivan has found that a daily consumption of 10mg of lutein and 2mg of zeaxanthin may help to slow the progression of AMD – increasing the health of the population and offering significant savings in public spending.